These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30687952)

  • 1. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection.
    Mettikanont P; Bunchorntavakul C; Reddy KR
    Aliment Pharmacol Ther; 2019 Mar; 49(5):492-505. PubMed ID: 30687952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
    Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
    J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis.
    Berden FA; Aaldering BR; Groenewoud H; IntHout J; Kievit W; Drenth JP
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):349-359. PubMed ID: 27840182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
    Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
    World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
    Bernhard B; Stickel F
    Z Gastroenterol; 2020 May; 58(5):451-455. PubMed ID: 32392606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
    Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
    Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
    Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
    Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
    Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
    Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
    Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
    J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
    Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Findings from a large Asian chronic hepatitis C real-life study.
    Lim SG; Phyo WW; Shah SR; Win KM; Hamid S; Piratvisuth T; Tan SS; Dan YY; Lee YM; Ahmed T; Yang WL; Chen KP; Kamat M; Wadhawan M; Madan K; Mehta R; Shukla A; Dhore P; Eapen CE; Abraham P; Tyagi S; Koshy A; Bwa AH; Jafri W; Abid S; Arisar FAQ; Tanwandee T; Yin TP; Tee HP; Hj Md Said RB; Goh KL; Ho SH; Mohamed R; Abu Bakar N
    J Viral Hepat; 2018 Dec; 25(12):1533-1542. PubMed ID: 30141214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A; Bhargava R; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis C: a systematic review.
    Kohli A; Shaffer A; Sherman A; Kottilil S
    JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
    Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
    Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatitis C: Results in real life.
    Hézode C
    Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.